DKK1

Jun 11, 2020

Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

May 14, 2020

Leap Therapeutics Reports First Quarter 2020 Financial Results

Apr 23, 2020

Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers

Apr 02, 2020

Imaging Endpoints' Novel Radiomics Technology Helps Identify DKK1 Biomarker

Mar 16, 2020

Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Jan 23, 2020

Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

Nov 14, 2019

Leap Therapeutics Reports Third Quarter 2019 Financial Results

Aug 09, 2019

Leap Therapeutics Reports Second Quarter 2019 Financial Results

Aug 06, 2019

Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update

Mar 18, 2019

Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

Mar 08, 2019

Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

Jan 14, 2019

Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer